| pubmed-article:18221398 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18221398 | lifeskim:mentions | umls-concept:C0684336 | lld:lifeskim |
| pubmed-article:18221398 | lifeskim:mentions | umls-concept:C0221002 | lld:lifeskim |
| pubmed-article:18221398 | lifeskim:mentions | umls-concept:C0911014 | lld:lifeskim |
| pubmed-article:18221398 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:18221398 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:18221398 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:18221398 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:18221398 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:18221398 | lifeskim:mentions | umls-concept:C1706089 | lld:lifeskim |
| pubmed-article:18221398 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:18221398 | pubmed:dateCreated | 2008-8-21 | lld:pubmed |
| pubmed-article:18221398 | pubmed:abstractText | Impaired GH secretion is a common finding in patients with primary hyperparathyroidism (PHP). Ghrelin displays strong GH-releasing action, mainly at the hypothalamic level. | lld:pubmed |
| pubmed-article:18221398 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18221398 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18221398 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18221398 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18221398 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18221398 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18221398 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18221398 | pubmed:issn | 1365-2265 | lld:pubmed |
| pubmed-article:18221398 | pubmed:author | pubmed-author:GhigoEE | lld:pubmed |
| pubmed-article:18221398 | pubmed:author | pubmed-author:MartinoEE | lld:pubmed |
| pubmed-article:18221398 | pubmed:author | pubmed-author:GasperiMM | lld:pubmed |
| pubmed-article:18221398 | pubmed:author | pubmed-author:BogazziFF | lld:pubmed |
| pubmed-article:18221398 | pubmed:author | pubmed-author:ProcopioMM | lld:pubmed |
| pubmed-article:18221398 | pubmed:author | pubmed-author:BroglioFF | lld:pubmed |
| pubmed-article:18221398 | pubmed:author | pubmed-author:GramagliaEE | lld:pubmed |
| pubmed-article:18221398 | pubmed:author | pubmed-author:CecconiEE | lld:pubmed |
| pubmed-article:18221398 | pubmed:author | pubmed-author:MorselliL LLL | lld:pubmed |
| pubmed-article:18221398 | pubmed:author | pubmed-author:GiovannettiCC | lld:pubmed |
| pubmed-article:18221398 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18221398 | pubmed:volume | 69 | lld:pubmed |
| pubmed-article:18221398 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18221398 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18221398 | pubmed:pagination | 197-201 | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:meshHeading | pubmed-meshheading:18221398... | lld:pubmed |
| pubmed-article:18221398 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18221398 | pubmed:articleTitle | Primary hyperparathyroidism is associated with marked impairment of GH response to acylated ghrelin. | lld:pubmed |
| pubmed-article:18221398 | pubmed:affiliation | Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy. | lld:pubmed |
| pubmed-article:18221398 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18221398 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:18221398 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
